Modeling poliovirus risks and the legacy of polio eradication

Risk Analysis

Volumn 33, Issue 4, 2013, Pages 505-515

  Thompson, Kimberly M ^a  

^a Kid Risk Inc   (United States)

Author keywords

Eradication; Modeling; Polio; Prevention

Indexed keywords

ERADICATION; POLICY DEVELOPMENT; POLIO; POLIO ERADICATION; POLIOVIRUS; PREVENTION;

MODELS; PHYSIOLOGY; RISK ANALYSIS; SAFETY ENGINEERING;

RISK MANAGEMENT;

POLIOMYELITIS VACCINE;

DISEASE CONTROL; DISEASE TRANSMISSION; HEALTH RISK; LITERATURE REVIEW; POLICY DEVELOPMENT; POLIOMYELITIS; RISK ASSESSMENT; RISK FACTOR;

ARTICLE; HUMAN; POLIOMYELITIS; RISK ASSESSMENT;

HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINES; RISK ASSESSMENT;

POLIOVIRUS;

EID: 84875915910     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12030     Document Type: Article

References (69)

1. World Health Assembly. Global Eradication of Poliomyelitis by the Year 2000 (resolution 41.28). Geneva: World Health Organization, 1988.
2. World Health Organization. Transmission of wild poliovirus type 2: Apparent global interruption. Weekly Epidemiological Record, 2001; 76:95-97.
3. Independent Monitoring Board of the Global Polio Eradication Initiative. Polio's Last Stand? November 2012 Report. Available at: http://www.polioeradication.org/Portals/0/Document/Aboutus/Governance/IMB/7IMBMeeting/7IMB_Report_EN.pdf, Accessed January 2, 2013.
4. Oshinsky D. Polio: An American Story. New York: Oxford University Press, 2005.
5. Francis T, Korns RF, Voight RB, Boisen M, Hemphill FM, Napier JA, Tolchinsky E. An evaluation of the 1954 poliomyelitis vaccine trials (summary report). American Journal of Public Health, 1955; 45(Part II, May Supplement):1-51.
6. Offit PA. The Cutter Incident. How America's First Polio Vaccine Led to the Growing Vaccine Crisis. New Haven, CT: Yale University Press, 2005.
7. Thompson KM, Duintjer Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Analysis, 2006; 26(6):1423-1440.
8. World Health Assembly. WHO Expanded Programme on Immunization (resolution 27.57). Geneva: World Health Organization, 1974.
9. de Quadros CA, Andrus JK, Olive JM, de Macedo CG, Henderson DA. Polio eradication from the western hemisphere. Annual Review of Public Health, 1992; 13:239-252.
10. Aylward RB. Lessons from the late stages of the Global Polio Eradication Initiative. Chapter 2 in Cochi SL and Dowdle WR (eds). Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: MIT Press, 2011.
11. Thompson KM. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. Risk Analysis, 2006; 26(6):1419-1421.
12. Aylward RB, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. Risk Analysis, 2006; 26(6):1441-1448.
13. Sangrujee NK, Duintjer Tebbens RJ, Cáceres VM, Thompson KM. Policy decision options during the first five years following certification of polio eradication. Medscape General Medicine, 2003; 5(4). Available at: http://www.medscape.com/viewarticle/464841, Accessed January 2, 2013.
14. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. American Journal of Epidemiology, 2005; 162(4):358-372.
15. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Analysis, 2006; 26(6):1471-1505.
16. Duintjer Tebbens RJ, Sangrujee N, Thompson KM. The costs of future polio risk management policies. Risk Analysis, 2006; 26(6):1507-1531.
17. de Gourville E, Duintjer Tebbens RJ, Sangrujee N, Pallansch MA, Thompson KM. Global surveillance and the value of information: The case of the global polio laboratory network. Risk Analysis, 2006; 26(6):1557-1569.
18. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of future global policies for managing polioviruses. American Journal of Public Health, 2008; 98(7):1322-1330.
19. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Analysis, 2008; 28(4):855-876.
20. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape Journal of Medicine 2008; 10(8):190. Available at: http://www.medscape.com/viewarticle/578396, Accessed January 2, 2013.
21. Barrett S. Stop! The polio vaccination cessation game. World Bank Economic Review, 2011; 24(3). doi:10.1093/wber/lhq018.
22. World Health Assembly. Poliomyelitis: Mechanism for Management of Potential Risks to Eradication (resolution 61.1). Geneva: World Health Organization, 2008.
23. Dowdle WR, van der Avoort H, de Gourville E, Delpeyroux F, Desphande J, Hovi T, Martin J, Pallansch MA, Kew OM, Wolff C. Containment of polioviruses after eradication and OPV cessation: Characterizing risks to improve management. Risk Analysis, 2006; 26(6):1449-1469.
24. Fine PEM, Ritchie S. Perspective: Determinants of the severity of poliovirus outbreaks in the post eradication era. Risk Analysis, 2006; 26(6):1533-1540.
25. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Analysis, 2006; 26(6):1541-1556.
26. Anon. Polio outbreak response: The faster, the better. Polio News, 2005; 25(Autumn):3. Available at: http://www.polioeradication.org/content/polionews/polionews25.pdf, Accessed on January 2, 2013.
27. World Health Assembly. Eradication of Poliomyelitis (resolution 59.1). Geneva: World Health Organization, 2006.
28. Rotary International. Rotary grants emergency funding for polio immunizations in Ethiopia. Available at: http://www.rotary9200.org/rotary9200/newsdetail.asp?NEWSID=12, Accessed January 2, 2013.
29. World Health Organization. Enhancing global poliovirus surveillance and outbreak response. 2010. Available at: http://www.polioeradication.org/Portals/0/Document/Media/FactSheet/EnhancingSurveillanceandOutbreakResponse.pdf, Accessed January 2, 2013.
30. Duintjer Tebbens RJ, Pallansch MA, Alexander J, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine, 2010; 28(26):4312-4327.
31. International Finance Facility for Immunisation. Polio eradication campaign: IFFIm helps lead the fight to eradicate polio. Available at: http://www.iffim.org/funding-gavi/results/polio-eradication-campaign/, Accessed January 2, 2013.
32. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander J, Venczel L, Johnson D, Cáceres VM, Sangrujee N, Jafari H, Cochi SL. Perspective: Development and consideration of global policies for managing the future risks of poliovirus outbreaks: Insights and lessons learned through modeling. Risk Analysis, 2006; 26(6):1571-1580.
33. Arita I, Nakane M, Fenner F. Is polio eradication realistic? Science, 2006; 312(5775):852-854.
34. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet, 2007; 369(9570):1363-1371.
35. World Health Organization. India records one year without polio cases. Available at: http://www.who.int/mediacentre/news/releases/2012/polio_20120113/en/index.html, Accessed January 2, 2013.
36. Kalkowska D, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. American Journal of Epidemiology, 2012; 175(9):936-949.
37. Center for Infectious Disease Research & Policy. Coalition declares "final push" to end polio. 2008. Available at: http://www.cidrap.umn.edu/cidrap/content/other/news/jun1808polio.html, Accessed January 2, 2013.
38. Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious diseases. Management Science, 2009; 55(4):650-663.
39. Thompson KM, Duintjer Tebbens RJ. Using system dynamics to develop policies that matter: Global management of poliomyelitis and beyond. System Dynamics Review, 2008; 24(4):433-449.
40. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SGF, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the Global Polio Eradication Initiative. Vaccine, 2011; 29(2):334-343.
41. World Health Organization. Vaccine development: Monovalent OPVs. Polio Pipeline, 2008; 2(Autumn):4-5. Available at: http://www.polioeradication.org/Research/PolioPipeline/No2Autumn2008Vaccinedevelopment.aspx, Accessed January 2, 2013.
42. World Health Organization. Programmatic benefits of bivalent OPV-"From bench to bush!" Polio Pipeline, 2010; 6(Autumn):1-2. Available at: http://www.polioeradication.org/Research/Poliopipeline/No6Summer2010/ProgrammaticbenefitsofbivalentOPV.aspx, Accessed January 2, 2013.
43. Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SGF. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Reports, 2012; 127(1):23-37.
44. Thompson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: Perspectives from modeling and prerequisites for OPV cessation. Expert Review of Vaccines, 2012; 11(4):449-459.
45. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Kim JH, Cochi SL. Pre-eradication national vaccine policy options for poliovirus infection and disease control. Risk Analysis, 2013; 33(4):516-543.
46. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Analysis, 2013; 33(4):544-605.
47. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SGF, Cochi SL, Kim J-H, Thompson KM. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis, 2013; 33(4):606-646.
48. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Analysis, 2013; 33(4):647-663.
49. Lowther S, Roesel S, O'Connor P, Landaverde M, Oblapenko G, Deshevoi S, Ajay G, Buff A, Safwar H, Mbaye S, Tangermann R, Khetsuriani N, Martin R, Wassilak S. Regional assessments of the risks of poliovirus outbreaks. Risk Analysis, 2013; 33(4):664-679.
50. Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste S, Diop O, Wassilak SGF, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses. Risk Analysis, 2013; 33(4):680-702.
51. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: Insights from modeling experiences with wild and vaccine-related polioviruses. Risk Analysis, 2013; 33(4):703-749.
52. Thompson KM. The role of risk analysis in polio eradication: Modeling possibilities, probabilities, and outcomes to inform choices. Expert Review of Vaccines, 2012; 11(1):5-7.
53. Thompson KM. Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases. ICU Management, 2012; in press.
54. Sabin AB. Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries. British Medical Journal (Clinical Research Edition), 1986; 292(6519):513-533.
55. World Health Assembly. Poliomyelitis: Intensification of the Global Eradication Initiative (resolution 65.20). Geneva: World Health Organization, 2012.
56. World Health Organization. IPV recommended for countries to mitigate risks and consequences associated with OPV2 withdrawal. Available at: http://www.who.int/immunization/sage/meetings/2012/november/news_sage_ipv_opv_nov2012/en/index.html, Accessed January 2, 2013.
57. Jenkins HE, Aylward RB, Gasasira A, Donnelly CA, Abanida EA, Koleosho-Adelekan T, Grassly NC. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. New England Journal of Medicine, 2008; 359(16):1666-1674.
58. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: A case-control study. Lancet, 2007; 369(9570):1356-1362.
59. O'Reilly KM, Chauvin C, Aylward RB, Maher C, Okiror S, Wolff C, Nshmirimana D, Donnelly CA, Grassly NC. A statistical model of the international spread of wild poliovirus in Africa used to predict and prevent outbreaks. PLoS Medicine, 2011; 8(10):e1001109.
60. Grassly NC, Fraser C, Wenger J, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. New strategies for the elimination of polio from India. Science, 2006; 314:1150-1153.
61. Grassly NC, Wenger J, Durrani S, Bahl S, Deshpande JM, Sutter RW, Heymann DL, Aylward RB. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: A case-control study. Lancet, 2007; 369:1356-1362.
62. Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM. Development of an individual-based model for polioviruses: Implications of the selection of network type and outcome metrics. Epidemiology and Infection, 2011; 139:836-848.
63. Duintjer Tebbens RJ, Thompson KM, Huninck M, Mazzuchi TM, Lewandowski D, Kurowicka D, Cooke RM. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Medical Decision Making, 2008; 28(2):182-200.
64. Thompson KM, Duintjer Tebbens RJ. Challenges related to the economic evaluation of the direct and indirect benefits and the costs of disease elimination and eradication efforts. Chapter 9 in Cochi SL, Dowdle WR (eds). Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: MIT Press, 2011.
65. Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker DG. Developing an eradication investment case. Chapter 10 in Cochi SL, Dowdle WR (eds). Disease Eradication in the 21st Century: Implications for Global Health. Cambridge, MA: MIT Press, 2011.
66. Thompson KM, Duintjer Tebbens RJ. Development of investment cases for globally-coordinated management of infectious diseases. Journal of Vaccines & Vaccination, 3:8. http://dx.doi.org/10.4172/2157-7560.1000164.
67. Hopkins JW. The Eradication of Smallpox: Organizational Learning and Innovation in International Health. Boulder, CO: Westview Press, 1989.
68. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and Its Eradication. Geneva, Switzerland: WHO, 1988.
69. World Health Organization. Global Vaccines Action Plan, 2012. Available at: http://www.dovcollaboration.org/action-plan/, Accessed on January 2, 2013.